GV led a $58.5m round for the heart disease drug developer, which is advancing research conducted at Harvard University and Broad Institute and has a partnership in place with Harvard spinout Beam Therapeutics.

TigerMed-backed brain monitor developer Neural Analytics boosted its total funding to $66m in a series C round led by existing investor Alpha Edison.

UMC Utrecht molecular diagnostics spinout Genome Diagnostics has won funding from Ampersand Capital Partners and will work with the private equity firm to spur business growth through activities including M&A.

Osage University Partners has invested in LunaPBC, the public benefit corporation responsible for operating the community-owned LunaDNA genetic and health data collection platform.

UCLA spinout Neural Analytics increased its total funding to $66m as it prepares for further testing of its robotically-assisted brain health monitoring platform.

Therachon, which had raised $100m from investors including Pfizer Ventures and Novo, has agreed to be acquired by Pfizer in a deal that could potentially reach $810m.

GV led a $58.5m round for the heart disease drug developer, which came in the wake of a partnership with another Alphabet subsidiary, Verily.

Pfizer will pay $340m upfront and up to an additional $470m in milestone payments to purchase its portfolio company Therachon, providing an exit to Inserm Transfert Initiative.

Bennett, Coleman & Co has exited online pharmacy Myra and will receive shares in its new owner, Medlife, as part of the acquisition deal.

Texas Medical Center was among the investors in a series A round for the nursing recruitment platform, a graduate of the corporate's accelerator.